4 results
It is expected that LF111 will offer benefits to adults in the form of efficacy similar to COCPs, absence of estrogen-related risks, reduced tendency to weight gain and extended dosing window. It is likely that adolescents will share these benefits…
Primary: Antiviral efficacy of dolutagravir in combination with Kivexa (abacavir en lamivudine) after 48 weeks of treatment in comparison with Atripla (tenofovir, emtricitabine and efavirenz). Secondary: Antiviral efficacy after 96 and 144 weeks,…
To examine the effects of mono- and combination therapy with linagliptin and empagliflozine on renal hemodynamics
The GO TEST OVERTURE study aims to demonstrate the superiority of the Treat to Target management strategy over a Treat to Avoid Symptoms approach in terms of clinical remission of gout symptoms.